CCL4 and melanoma: An intravenous infusion of the collagen-binding domain of von Willebrand factor conjugated with CCL4 recruited more CD103+ and CD8+ T cells into the a melanoma and breast cancer mouse model and improved the immunotherapy’s efficacy [65].